Genistein, a natural product derived from soybeans, ameliorates polyglutamine-mediated motor neuron disease

Journal of Neurochemistry

Volumn 126, Issue 1, 2013, Pages 122-130

  Qiang, Qiang ^a   Adachi, Hiroaki ^a   Huang, Zhe ^a   Jiang, Yue Mei ^a   Katsuno, Masahisa ^a   Minamiyama, Makoto ^a   Doi, Hideki ^a   Matsumoto, Shinjiro ^a   Kondo, Naohide ^a   Miyazaki, Yu ^a   Iida, Madoka ^a   Tohnai, Genki ^a   Sobue, Gen ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

androgen receptor; ARA70; genistein; motor neuron disease; polyglutamine disease; SBMA

Indexed keywords

ANDROGEN RECEPTOR; ARA70 PROTEIN; CELL PROTEIN; GENISTEIN; MONOMER; POLYGLUTAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; KENNEDY DISEASE; MALE; MOLECULAR WEIGHT; MUSCLE DISEASE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SPINAL CORD DISEASE; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CELLS, CULTURED; DNA, COMPLEMENTARY; GENISTEIN; IMMUNOHISTOCHEMISTRY; LUCIFERASES; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOTOR NEURON DISEASE; MUSCLE, SKELETAL; MUSCULAR DISORDERS, ATROPHIC; NEUROPROTECTIVE AGENTS; NUCLEAR RECEPTOR COACTIVATORS; PEPTIDES; RECEPTORS, ANDROGEN; SPINAL CORD;

GLYCINE MAX; MUS MUSCULUS;

EID: 84879416790     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12172     Document Type: Article

References (40)

1. Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Do J., Sang C., Kobayashi Y., Doyu M., and, Sobue G., (2001) Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet. 10, 1039-1048.
2. Adachi H., Katsuno M., Minamiyama M., et al,. (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 23, 2203-2211.
3. Adachi H., Katsuno M., Minamiyama M., et al,. (2005) Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128, 659-670.
4. Adachi H., Waza M., Katsuno M., Tanaka F., Doyu M., and, Sobue G., (2007a) Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol. Appl. Neurobiol. 33, 135-151.
5. Adachi H., Waza M., Tokui K., Katsuno M., Minamiyama M., Tanaka F., Doyu M., and, Sobue G., (2007b) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 27, 5115-5126.
6. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and, Fukami Y., (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595.
7. Bang O. Y., Hong H. S., Kim D. H., Kim H., Boo J. H., Huh K., and, Mook-Jung I., (2004) Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiol. Dis. 16, 21-28.
8. Chymkowitch P., Le May N., Charneau P., Compe E., and, Egly J. M., (2011) The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J. 30, 468-479.
9. Fernandez-Rhodes L. E., Kokkinis A. D., White M. J., et al,. (2011) Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 10, 140-147.
10. Heinlein C. A., and, Chang C., (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23, 175-200.
11. Hu Y. C., Yeh S., Yeh S. D., et al,. (2004) Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 279, 33438-33446.
12. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., and, Sobue G., (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854.
13. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A., and, Sobue G., (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9, 768-773.
14. Katsuno M., Banno H., Suzuki K., et al,. (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 875-884.
15. Kennedy W. R., Alter M., and, Sung J. H., (1968) Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671-680.
16. Kobayashi Y., Kume A., Li M., Doyu M., Hata M., Ohtsuka K., and, Sobue G., (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275, 8772-8778.
17. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., and, Fischbeck K. H., (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79.
18. LaFevre-Bernt M. A., and, Ellerby L. M., (2003) Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J. Biol. Chem. 278, 34918-34924.
19. Levitzki A., and, Gazit A., (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788.
20. Lin H. K., Yeh S., Kang H. Y., and, Chang C., (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl Acad. Sci. USA 98, 7200-7205.
21. Lin H. K., Wang L., Hu Y. C., Altuwaijri S., and, Chang C., (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21, 4037-4048.
22. Liu L. X., Chen W. F., Xie J. X., and, Wong M. S., (2008) Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci. Res. 60, 156-161.
23. McClain R. M., Wolz E., Davidovich A., Pfannkuch F., and, Bausch J., (2005) Subchronic and chronic safety studies with genistein in dogs. Food Chem. Toxicol. 43, 1461-1482.
24. Messina S., Bitto A., Aguennouz M., et al,. (2011) The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-alpha activation and ameliorates muscle function and morphology in mdx mice. Neuromuscul. Disord. 21, 579-589.
25. Michael Mc Clain R., Wolz E., Davidovich A., Pfannkuch F., Edwards J. A., and, Bausch J., (2006) Acute, subchronic and chronic safety studies with genistein in rats. Food Chem. Toxicol. 44, 56-80.
26. Miyazaki Y., Adachi H., Katsuno M., et al,. (2012) Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat. Med. 18, 1136-1141.
27. Orr H. T., and, Zoghbi H. Y., (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621.
28. Palazzolo I., Stack C., Kong L., et al,. (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63, 316-328.
29. Parodi S., and, Pennuto M., (2011) Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front. Neuroendocrinol. 32, 416-425.
30. Ponguta L. A., Gregory C. W., French F. S., and, Wilson E. M., (2008) Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J. Biol. Chem. 283, 20989-21001.
31. Rinaldi C., Bott L. C., Chen K. L., Harmison G. G., Katsuno M., Sobue G., Pennuto M., and, Fischbeck K. H., (2012) Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Mol. Med. 18, 1261-1268.
32. Sobue G., Hashizume Y., Mukai E., Hirayama M., Mitsuma T., and, Takahashi A., (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112, 209-232.
33. Tokui K., Adachi H., Waza M., et al,. (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18, 898-910.
34. Trieu V. N., and, Uckun F. M., (1999) Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun. 258, 685-688.
35. Tsai T. H., (2005) Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J. Chromatogr. A 1073, 317-322.
36. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M., and, Sobue G., (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11, 1088-1095.
37. Yan G. R., Xiao C. L., He G. W., Yin X. F., Chen N. P., Cao Y., and, He Q. Y., (2010) Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 10, 976-986.
38. Yang Z., Chang Y. J., Yu I. C., et al,. (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med. 13, 348-353.
39. Yeh S., and, Chang C., (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl Acad. Sci. USA 93, 5517-5521.
40. Yeh S., Lin H. K., Kang H. Y., Thin T. H., Lin M. F., and, Chang C., (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA 96, 5458-5463. Japan